Al Jalila Foundation’s diabetes treatment programme receives AED 5 million donation from Landmark Group
Al Jalila Foundation, a philanthropic non-profit organisation dedicated to changing lives through medical innovation, has announced that Landmark Group, the region’s leading retail and hospitality conglomerate, will support the foundation’s A’awen Diabetes Treatment Programme with a total contribution of AED 5 million over the next five years. The pledged amount is being raised by Landmark Group as part of its flagship social initiative ‘Conquer Diabetes’.
Launched in 2013, the Al Jalila Foundation’s A’awen (‘support’ in Arabic) treatment programme aims to provide financial assistance to UAE citizens and residents who suffer from life-threatening diseases and cannot afford access to quality healthcare. The programme supports patients by alleviating much of their financial burden.
As part of its ‘Beat Diabetes’ initiative, Landmark Group raises funds through its extensive network of branded shops in the UAE for Al Jalila Foundation’s diabetes research and treatment programmes. Going a step further in this direction, the group is supporting donations collected in shops dirham by dirham, doubling the amount raised, and will continue to do so in the future.
The funds raised by Landmark Group will go to support diabetic patients who are eligible for financial assistance after consideration by the A’awen committee of the Al Jalila Foundation, which is made up of subject matter experts and doctors. The Al Jalila Foundation is addressing the needs of patients by working with its healthcare partners on treatment plans, and will provide a progress report on the fundraising initiative and its positive impact.
Renuka Jagtiani, chairman and CEO of Landmark Group, said: “We have been supporting the fight against diabetes in the UAE for more than a decade, with a long-standing goal of raising awareness about this difficult but preventable disease. Diabetes is one of the leading causes of some debilitating diseases in the world and many financially challenged patients are unable to get the treatment they need. Our five-year contribution to the Al Jalil Foundation’s A’awen treatment programme is a vital step towards providing easier access to life-saving health services for those who need them.”
Dr Abdulkarim Sultan Al Olama, CEO of Al Jalil Foundation, said: “Through our partnership with Landmark Group, we have been able to make significant progress in diabetes research to improve patient care. According to the World Health Organization (WHO), at least 422 million people worldwide have diabetes and 1.5 million deaths each year are directly linked to diabetes. This requires urgent action and cooperation. Investing in research will help us find relevant and innovative solutions to one of the most pressing health challenges, and we thank the Landmark Group for its continued support and contribution to diabetes research, prevention and treatment.”
Since 2014, Landmark Group’s Beat Diabetes initiative has raised and contributed more than AED 13 million to diabetes research and treatment. In 2021, Landmark Group held its 12th Beat Diabetes Walk, a one-day event bringing together more than 10,000 participants to educate the public about the disease.
In recognition of its commitment to diabetes, the conglomerate is the first and only corporation from the Gulf region to be listed as a member of the Global Diabetes Compact Forum. Founded by the World Health Organization (WHO), the Forum aims to create a world where the risk of developing diabetes (type 1 and type 2) is reduced and people diagnosed with the disease have access to equitable, comprehensive, affordable and quality treatment and care.
Landmark Group to support Al Jalila Foundation’s (@aljalilauae) A’awen diabetes treatment programme with a total contribution of AED5 million over the next five years. #Dubai https://t.co/kxTkerP07L pic.twitter.com/21Aexay7XD
— Dubai Media Office (@DXBMediaOffice) February 16, 2022
Follow our Telegram Chanel
